JAZZ

Bullish

Jazz Pharmaceuticals' New Cancer Drug Drives $1.3 Billion Opportunity, Says Analyst

BofA Securities analyst Jason Gerberry reaffirmed a Buy rating for Jazz Pharmaceuticals (JAZZ) and raised the price target to $307, citing the firm's ...

Benzinga 2 weeks ago 0

Neutral

Assessing Jazz Pharmaceuticals (JAZZ) Valuation After Xywav And Ziihera Updates And Strong Quarterly Results

Jazz Pharmaceuticals (JAZZ) has shown strong performance with recent updates on its sleep and oncology portfolios, including Xywav and Ziihera, and be...

Simply Wall Street 2 weeks ago 0